| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 14.2% | $84.1M | 8.83M | BVF PARTNERS L P/IL | 31 Mar 2025 | |||
| Lynx1 Capital Management LP | 13.9% | +37% | $123M | $32.1M | 8.6M | +35.4% | LYNX1 CAPITAL MANAGEMENT LP | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 12.4% | +10.9% | $123M | $11.7M | 7.68M | +10.5% | RA Capital Management, L.P. | 30 Jun 2025 |
| RTW INVESTMENTS, LP | 8.9% | $52.4M | 5.5M | RTW Investments, LP | 31 Mar 2025 | |||
| FMR LLC | 8.2% | +18.6% | $81.7M | $13.5M | 5.09M | +19.8% | FMR LLC | 30 Jun 2025 |
| Terwey Theis H | 2.9% | -58.8% | $25.5M | -$41.6M | 1.78M | -62% | Terwey Theis H | 30 Sep 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 44.5M | $618M | +$14.4M | $14.30 | 47 |
| 2025 Q2 | 43.6M | $531M | +$12.4M | $12.19 | 37 |
| 2025 Q1 | 42.6M | $470M | +$133M | $11.03 | 35 |
| 2024 Q4 | 30.7M | $215M | +$703K | $7.00 | 31 |
| 2024 Q3 | 30.5M | $204M | +$470K | $6.69 | 28 |
| 2024 Q2 | 30.4M | $355M | +$9.91M | $11.66 | 28 |
| 2024 Q1 | 29.6M | $316M | +$9.7M | $10.66 | 32 |
| 2023 Q4 | 29.6M | $172M | +$1.76M | $5.80 | 35 |
| 2023 Q3 | 29M | $291M | -$8.21M | $10.05 | 29 |
| 2023 Q2 | 29.6M | $352M | -$694K | $11.87 | 34 |
| 2023 Q1 | 29.7M | $237M | -$9.78M | $7.99 | 29 |
| 2022 Q4 | 30.9M | $299M | -$7.76M | $9.72 | 32 |
| 2022 Q3 | 31.6M | $367M | -$9.45M | $11.62 | 33 |
| 2022 Q2 | 32.6M | $325M | +$3.74M | $9.98 | 33 |
| 2022 Q1 | 32.1M | $587M | +$37.2M | $18.29 | 30 |
| 2021 Q4 | 30M | $701M | +$27M | $23.33 | 29 |
| 2021 Q3 | 28.5M | $625M | +$21.3M | $22.06 | 29 |
| 2021 Q2 | 27.6M | $594M | +$594M | $21.73 | 34 |